Peter Klivenyi

List of Publications by Year in descending order

169 papers	8,905 citations	87723 38 h-index	43802 91 g-index
182 all docs	182 docs citations	182 times ranked	10831 citing authors

#	Article	IF	Citations
1	Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine. Journal of Neuroscience, 2000, 20, 1-7.	1.7	2,029
2	Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine, 1999, 5, 347-350.	15.2	669
3	Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nature Biotechnology, 2003, 21, 1200-1207.	9.4	585
4	Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease. Journal of Biological Chemistry, 2005, 280, 556-563.	1.6	401
5	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
6	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
7	Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity. Experimental Neurology, 1999, 157, 142-149.	2.0	326
8	Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of Disease, 2006, 21, 541-548.	2.1	185
9	Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 2003, 88, 576-582.	2.1	171
10	Nonlinear Decrease over Time in N-Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice. Journal of Neurochemistry, 2008, 74, 2108-2119.	2.1	156
11	Manganese Superoxide Dismutase Overexpression Attenuates MPTP Toxicity. Neurobiology of Disease, 1998, 5, 253-258.	2.1	138
12	N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. NeuroReport, 2000, 11, 2491-2493.	0.6	128
13	The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection. Journal of the Neurological Sciences, 2009, 283, 21-27.	0.3	109
14	Mice with a Partial Deficiency of Manganese Superoxide Dismutase Show Increased Vulnerability to the Mitochondrial Toxins Malonate, 3-Nitropropionic Acid, and MPTP. Experimental Neurology, 2001, 167, 189-195.	2.0	103
15	Kynurenine metabolism in multiple sclerosis. Acta Neurologica Scandinavica, 2005, 112, 93-96.	1.0	93
16	Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3â€nitropropionic acid neurotoxicity. Journal of Neurochemistry, 2004, 88, 1352-1360.	2.1	92
17	Neuroprotective Effects of Phenylbutyrate Against MPTP Neurotoxicity. NeuroMolecular Medicine, 2004, 5, 235-242.	1.8	91
18	Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntingtonâ€™s disease. Journal of Neural Transmission, 2011, 118, 865-875.	1.4	87

#	Article	IF	Citations
19	Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacology Biochemistry and Behavior, 2009, 94, 148-153.	1.3	84
20	Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. Journal of the Neurological Sciences, 2005, 239, 31-35.	0.3	83
21	Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. Journal of Neural Transmission, 2009, 116, 1403-1409.	1.4	78
22	Alzheimerâ€™s Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. Journal of Alzheimer's Disease, 2018, 62, 523-547.	1.2	75
23	Additive Neuroprotective Effects of Creatine and a Cyclooxygenase 2 Inhibitor Against Dopamine Depletion in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease. Journal of Molecular Neuroscience, 2003, 21, 191-198.	1.1	74
24	Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disorders. Journal of the Neurological Sciences, 2012, 322, 187-191.	0.3	71
25	Nonenzymatic antioxidants of blood in multiple sclerosis. Journal of Neurology, 1999, 246, 533-539.	1.8	70
26	Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Annals of Neurology, 2000, 47, 447-455.	2.8	69
27	Glutamatergic Dysfunctioning in Alzheimer's Disease and Related Therapeutic Targets. Journal of Alzheimer's Disease, 2014, 42, S177-S187.	1.2	64
28	Increased glucose metabolism and ATP level in brain tissue of Huntingtonâ€™s disease transgenic mice. FEBS Journal, 2008, 275, 4740-4755.	2.2	60
29	Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. NeuroReport, 2000, 11, 1265-1268.	0.6	59
30	Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2004, 86, 267-272.	2.1	56
31	Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiology of Disease, 2004, 15, 610-617.	2.1	54
32	Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects. Current Medicinal Chemistry, 2012, 19, 1899-1920.	1.2	53
33	Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians. Neuroscience Letters, 2013, 551, 70-74.	1.0	53
34	Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosisâ€“osteopontin as a potential marker of clinical severity. Journal of the Neurological Sciences, 2013, 331, 38-42.	0.3	52
35	Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. Journal of Cellular and Molecular Medicine, 2011, 15, 701-717.	1.6	50
36	Manipulating Kynurenic Acid Levels in the Brain â€“ On the Edge Between Neuroprotection and Cognitive Dysfunction. Current Topics in Medicinal Chemistry, 2012, 12, 1797-1806.	1.0	49

#	Article	IF	Citations
37	Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinsonâ€™s disease. Brain Research, 2020, 1730, 146672.	1.1	45
38	Malonate and 3-Nitropropionic Acid Neurotoxicity Are Reduced in Transgenic Mice Expressing a Caspase-1 Dominant-Negative Mutant. Journal of Neurochemistry, 2002, 75, 847-852.	2.1	43
39	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 573-595.	1.4	38
40	The Prevalence of Multiple Sclerosis, Distribution of Clinical Forms of the Disease and Functional Status of Patients in CsongrÃ¡d County, Hungary. European Neurology, 2001, 46, 206-209.	0.6	37
41	Language deficits in pre-symptomatic Huntingtonâ€™s disease: Evidence from Hungarian. Brain and Language, 2012, 121, 248-253.	0.8	37
42	Neuroprotection in Parkinsonâ€™s disease: facts and hopes. Journal of Neural Transmission, 2020, 127, 821-829.	1.4	37
43	Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinsonâ€™s disease: An open-label study. Parkinsonism and Related Disorders, 2017, 37, 79-86.	1.1	36
44	Non-invasive Brain Stimulation in Alzheimer's Disease and Mild Cognitive Impairmentâ€”A State-of-the-Art Review on Methodological Characteristics and Stimulation Parameters. Frontiers in Human Neuroscience, 2020, 14, 179.	1.0	35
45	Kynurenines in Parkinsonâ€™s disease: therapeutic perspectives. Journal of Neural Transmission, 2012, 119, 275-283.	1.4	34
46	Novel Free Radical Spin Traps Protect against Malonate and MPTP Neurotoxicity. Experimental Neurology, 1999, 157, 120-126.	2.0	33
47	Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. Biomedicine and Pharmacotherapy, 2010, 64, 282-286.	2.5	33
48	Genetic background of the hereditary spastic paraplegia phenotypes in Hungary â€” An analysis of 58 probands. Journal of the Neurological Sciences, 2016, 364, 116-121.	0.3	32
49	Comprehensive Genetic Analysis of a Hungarian Amyotrophic Lateral Sclerosis Cohort. Frontiers in Genetics, 2019, 10, 732.	1.1	31
50	Novel AARS2 gene mutation producing leukodystrophy: a case report. Journal of Human Genetics, 2017, 62, 329-333.	1.1	29
51	Kynurenines in Neurodegenerative Disorders: Therapeutic Consideration. Advances in Experimental Medicine and Biology, 2004, 541, 169-183.	0.8	29
52	Target Identification for Stereotactic Thalamotomy Using Diffusion Tractography. PLoS ONE, 2012, 7, e29969.	1.1	28
53	Drug-induced movement disorders. Expert Opinion on Drug Safety, 2015, 14, 877-890.	1.0	27
54	Targeting the Kynurenine Pathway-Related Alterations in Alzheimer's Disease: A Future Therapeutic Strategy. Journal of Alzheimer's Disease, 2011, 24, 199-209.	1.2	26

#	Article	IF	Citations
55	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	2.8	26
56	Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. Current Topics in Medicinal Chemistry, 2012, 12, 1797-806.	1.0	25
57	Novel therapeutic strategies in Parkinsonâ€™s disease. European Journal of Clinical Pharmacology, 2010, 66, 119-125.	0.8	24
58	Highâ€throughput sequencing revealed a novel <scp>SETX</scp> mutation in a Hungarian patient with amyotrophic lateral sclerosis. Brain and Behavior, 2017, 7, e00669.	1.0	24
59	Synthesis and biological effects of some kynurenic acid analogs. Bioorganic and Medicinal Chemistry, 2011, 19, 7590-7596.	1.4	23
60	Behaviour changes in a transgenic model of Huntington's disease. Behavioural Brain Research, 2006, 169, 137-141.	1.2	22
61	A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis. Biochemical and Biophysical Research Communications, 2011, 409, 137-141.	1.0	22
62	Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Letters, 2013, 554, 131-134.	1.0	22
63	Electron Transport Disturbances and Neurodegeneration: From Albert Szent-GyÃ¶rgyiâ€™s Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-19.	1.9	22
64	Neuroprotective effects of probenecid in a transgenic animal model of Huntingtonâ€™s disease. Journal of Neural Transmission, 2009, 116, 1079-1086.	1.4	20
65	Manipulating Kynurenic Acid Levels in the Brain â€“ On the Edge Between Neuroprotection and Cognitive Dysfunction. Current Topics in Medicinal Chemistry, 2012, 12, 1797-1806.	1.0	20
66	B7 costimulation and intracellular indoleamine-2,3-dioxygenase (IDO) expression in peripheral blood of healthy pregnant and non-pregnant women. BMC Pregnancy and Childbirth, 2014, 14, 306.	0.9	20
67	Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington's disease. Pharmacology Biochemistry and Behavior, 2015, 132, 115-124.	1.3	20
68	An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinsonâ€™s disease. Neuroscience Letters, 2016, 610, 135-138.	1.0	20
69	Azulenyl Nitrone Spin Traps Protect against MPTP Neurotoxicity. Experimental Neurology, 1998, 152, 163-166.	2.0	19
70	Transgenic ALS Mice Show Increased Vulnerability to the Mitochondrial Toxins MPTP and 3-Nitropropionic Acid. Experimental Neurology, 2001, 168, 356-363.	2.0	19
71	Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series. Neurological Sciences, 2017, 38, 481-483.	0.9	18
72	Opicapone for the treatment of Parkinsonâ€™s disease: an update. Expert Opinion on Pharmacotherapy, 2019, 20, 2201-2207.	0.9	18

#	Article	IF	Citations
73	Neuropathology of Partial PGC-1Î± Deficiency Recapitulates Features of Mitochondrial Encephalopathies but Not of Neurodegenerative Diseases. Neurodegenerative Diseases, 2013, 12, 177-188.	0.8	17
74	Independent validation of Parkinsonâ€™s disease Sleep Scale 2nd version (PDSS-2). Sleep and Biological Rhythms, 2016, 14, 63-73.	0.5	17
75	Genetic analysis of the SOD1 and C9ORF72 genes in Hungarian patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2017, 53, 195.e1-195.e5.	1.5	17
76	The rs13388259 Intergenic Polymorphism in the Genomic Context of theBCYRN1Gene Is Associated with Parkinsonâ€™s Disease in the Hungarian Population. Parkinson's Disease, 2018, 2018, 1-7.	0.6	17
77	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. International Journal of Alzheimer's Disease, 2010, 2010, 1-12.	1.1	16
78	Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinsonâ€™s disease. Journal of Neural Transmission, 2013, 120, 673-681.	1.4	16
79	Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner. Neuropharmacology, 2015, 89, 298-307.	2.0	15
80	Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntingtonâ€™s disease. Expert Opinion on Therapeutic Targets, 2019, 23, 39-51.	1.5	15
81	The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. Frontiers in Neurology, 2021, 12, 677551.	1.1	15
82	Histopathological comparison of Kearns-Sayre syndrome and PGC-1Î±-deficient mice suggests aÂnovel concept for vacuole formation in mitochondrial encephalopathy. Folia Neuropathologica, 2016, 1, 9-22.	0.5	15
83	Proteomics in Multiple Sclerosis: The Perspective of the Clinician. International Journal of Molecular Sciences, 2022, 23, 5162.	1.8	15
84	Somatostatin and Alzheimer's disease. Archives of Gerontology and Geriatrics, 1995, 21, 35-41.	1.4	14
85	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012â€“2015). Expert Opinion on Therapeutic Patents, 2016, 26, 815-832.	2.4	14
86	Alpha-Tocopherol and NADPH in the Erythrocytes and Plasma of Multiple Sclerosis Patients. European Neurology, 2003, 50, 215-219.	0.6	13
87	Neuroprotective Effects of Oral Administration of Triacetyluridine Against MPTP Neurotoxicity. NeuroMolecular Medicine, 2005, 6, 087-092.	1.8	13
88	Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep Problems and Daytime Sleepiness in Parkinsonâ€™s Disease?. Parkinson's Disease, 2014, 2014, 1-8.	0.6	13
89	Effect of MPTP on mRNA expression of PGC-1Î± in mouse brain. Brain Research, 2017, 1660, 20-26.	1.1	13
90	Epidemiology of multiple sclerosis in Central Europe, update from Hungary. Brain and Behavior, 2020, 10, e01598.	1.0	13

#	Article	IF	Citations
91	Neuroimaging and cognitive changes during dÃ©jÃ vu. Epilepsy and Behavior, 2009, 14, 190-196.	0.9	12
92	Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 540-543.	1.4	12
93	Relevance of defensin Î²-2 and Î± defensins (HNP1-3) in Alzheimer's disease. Psychiatry Research, 2016, 239, 342-345.	1.7	12
94	mRNA Expression Levels of PGC-1Î± in a Transgenic and a Toxin Model of Huntingtonâ€™s Disease. Cellular and Molecular Neurobiology, 2015, 35, 293-301.	1.7	11
95	Effect of subthalamic stimulation on distal and proximal upper limb movements in Parkinson's disease. Brain Research, 2016, 1648, 438-444.	1.1	11
96	Lack of age-related clinical progression in PGC-1Î±-deficient mice â€“ implications for mitochondrial encephalopathies. Behavioural Brain Research, 2016, 313, 272-281.	1.2	11
97	Neurotransmitter and tryptophan metabolite concentration changes in the complete Freundâ€™s adjuvant model of orofacial pain. Journal of Headache and Pain, 2020, 21, 35.	2.5	11
98	NEAT1 on the Field of Parkinsonâ€™s Disease: Offense, Defense, or a Player on the Bench?. Journal of Parkinson's Disease, 2021, 11, 123-138.	1.5	11
99	Gene variants and expression changes of SIRT1 and SIRT6 in peripheral blood are associated with Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 10677.	1.6	11
100	What is the impact of catechol-O-methyltransferase (COMT) on Parkinsonâ€™s disease treatment?. Expert Opinion on Pharmacotherapy, 2022, 23, 1123-1128.	0.9	11
101	Angiogenin mutations in Hungarian patients with amyotrophic lateral sclerosis: Clinical, genetic, computational, and functional analyses. Brain and Behavior, 2019, 9, e01293.	1.0	10
102	Predictors of localization, outcome, and etiology of spontaneous intracerebral hemorrhages: focus on cerebral amyloid angiopathy. Journal of Neural Transmission, 2020, 127, 963-972.	1.4	10
103	Investigation of vitamin D receptor polymorphisms in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2016, 133, 302-308.	1.0	9
104	Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Letters, 2017, 651, 128-133.	1.0	9
105	Neurocognitive Characterization of an SCA28 Family Caused by a Novel AFG3L2 Gene Mutation. Cerebellum, 2017, 16, 979-985.	1.4	9
106	Non-motor Behavioral Alterations of PGC-1Î±-Deficient Mice â€“ A Peculiar Phenotype With Slight Male Preponderance and No Apparent Progression. Frontiers in Behavioral Neuroscience, 2018, 12, 180.	1.0	9
107	The Role of Genetic Testing in the Clinical Practice and Research of Early-Onset Parkinsonian Disorders in a Hungarian Cohort: Increasing Challenge in Genetic Counselling, Improving Chances in Stratification for Clinical Trials. Frontiers in Genetics, 2019, 10, 1061.	1.1	9
108	Altered brain network function during attention-modulated visual processing in multiple sclerosis. Multiple Sclerosis Journal, 2020, 27, 135245852095836.	1.4	9

#	Article	IF	Citations
109	Clinicopathological Relationships in an Aged Case of DOORS Syndrome With a p.Arg506X Mutation in the ATP6V1B2 Gene. Frontiers in Neurology, 2020, 11, 767.	1.1	9
110	Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations. International Journal of Molecular Sciences, 2022, 23, 3383.	1.8	9
111	Effects of Mitochondrial Toxins on the Brain Amino Acid Concentrations. Neurochemical Research, 2005, 30, 1421-1427.	1.6	8
112	Cognitive Functions in Ataxia with Oculomotor Apraxia Type 2. Frontiers in Neurology, 2012, 3, 125.	1.1	8
113	The Genetic Link between Parkinsonâ€™s Disease and the Kynurenine Pathway Is Still Missing. Parkinson's Disease, 2015, 2015, 1-7.	0.6	8
114	Postnatal outcome and placental blood flow after plasmapheresis during pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 30, 1-4.	0.7	8
115	Voxel-based asymmetry of the regional gray matter over the inferior temporal gyrus correlates with depressive symptoms in medicated patients with major depressive disorder. Psychiatry Research - Neuroimaging, 2021, 317, 111378.	0.9	8
116	Realâ€world user experience with seizure detection wearable devices in the home environment. Epilepsia, 2023, 64, .	2.6	8
117	Effects of valproate on the dopaminergic system in mice. Neurological Research, 2009, 31, 217-219.	0.6	7
118	The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimerâ€™s Disease: Shortcomings in Prodromal Diagnosis. Journal of Alzheimer's Disease, 2016, 53, 373-392.	1.2	7
119	The establishment of tocopherol reference intervals for Hungarian adult population using a validated HPLC method. Biomedical Chromatography, 2017, 31, e3953.	0.8	7
120	The effect of physical stimuli on the expression level of key elements in mitochondrial biogenesis. Neuroscience Letters, 2019, 698, 13-18.	1.0	7
121	Cuprizone markedly decreases kynurenic acid levels in the rodent brain tissue and plasma. Heliyon, 2021, 7, e06124.	1.4	7
122	High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice. Acta Neurobiologiae Experimentalis, 2016, 76, 176-181.	0.4	7
123	Webâ€based decision support system for patientâ€tailored selection of antiseizure medication in adolescents and adults: An external validation study. European Journal of Neurology, 2022, 29, 382-389.	1.7	7
124	Selecting dopamine depleters for hyperkinetic movement disorders: how do we choose?. Expert Opinion on Pharmacotherapy, 2020, 21, 1-4.	0.9	6
125	Fixed-dose combination therapy for Parkinsonâ€™s disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime. Expert Opinion on Pharmacotherapy, 2020, 21, 2265-2278.	0.9	6
126	The Effects of Bilateral Theta-burst Stimulation on Executive Functions and Affective Symptoms in Major Depressive Disorder. Neuroscience, 2021, 461, 130-139.	1.1	5

#	Article	IF	Citations
127	A novel SETX gene mutation producing ataxia with oculomotor apraxia type 2. Acta Neurologica Belgica, 2016, 116, 405-407.	0.5	4
128	Pediatric multiple sclerosis and fulminant disease course: Features and approaches to treatment â€“ A case report and review of the literature. Journal of Clinical Neuroscience, 2018, 53, 13-19.	0.8	4
129	Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinsonâ€™s disease patients. Neuroscience Letters, 2019, 706, 140-145.	1.0	4
130	Predominant neurological phenotype in a Hungarian family with two novel mutations in the XPA geneâ€”case series. Neurological Sciences, 2020, 41, 125-129.	0.9	4
131	Cerebellar Predominant Increase in mRNA Expression Levels of Sirt1 and Sirt3 Isoforms in a Transgenic Mouse Model of Huntingtonâ€™s Disease. Neurochemical Research, 2020, 45, 2072-2081.	1.6	4
132	Two Classes of T1 Hypointense Lesions in Multiple Sclerosis With Different Clinical Relevance. Frontiers in Neurology, 2021, 12, 619135.	1.1	4
133	LÃ©gzÃ©si elÃ©gtelensÃ©ggel jÃ¡rÃ³ CANOMAD szindrÃ³ma. Ideggyogyaszati Szemle, 2020, 73, 141-144.	0.4	4
134	Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias. CNS and Neurological Disorders - Drug Targets, 2019, 18, 279-293.	0.8	4
135	Diffusion MRI measured white matter microstructure as a biomarker of neurodegeneration in preclinical Huntington's disease. Ideggyogyaszati Szemle, 2013, 66, 399-405.	0.4	4
136	Do Hungarian multiple sclerosis care units fulfil international criteria?. PLoS ONE, 2022, 17, e0264328.	1.1	4
137	Genetic landscape of early-onset dementia in Hungary. Neurological Sciences, 0, , .	0.9	4
138	The detection of age-, gender-, and region-specific changes in mouse brain tocopherol levels via the application of different validated HPLC methods. Neurochemical Research, 2018, 43, 2081-2091.	1.6	3
139	24-Hour Near-Infrared Spectroscopy Monitoring of Acute Ischaemic Stroke Patients Undergoing Thrombolysis or Thrombectomy: A Pilot Study. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2337-2342.	0.7	3
140	Functional Connectivity Lateralisation Shift of Resting State Networks is Linked to Visuospatial Memory and White Matter Microstructure in Relapsingâ€“Remitting Multiple Sclerosis. Brain Topography, 2022, 35, 268-275.	0.8	3
141	Factors affecting postural instability after more than one-year bilateral subthalamic stimulation in Parkinsonâ€™s disease: A cross-sectional study. PLoS ONE, 2022, 17, e0264114.	1.1	3
142	Re-analysis of the Hungarian amyotrophic lateral sclerosis population and evaluation of novel ALS genetic risk variants. Neurobiology of Aging, 2022, 116, 1-11.	1.5	3
143	Peripheral Kynurenine Metabolism in Focal Dystonia. Medicinal Chemistry, 2007, 3, 285-288.	0.7	2
144	Pharmacological Models of Parkinsonâ€™s Disease in Rodents. Methods in Molecular Biology, 2011, 793, 211-227.	0.4	2

#	Article	IF	Citations
145	The Report of p.Val717Phe Mutation in the APP Gene in a Hungarian Family With Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2017, 31, 343-345.	0.6	2
146	Editorial: Antiplatelet Agents in Stroke Prevention. Frontiers in Neurology, 2021, 12, 762060.	1.1	2
147	Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. Ideggyogyaszati Szemle, 2019, 72, 39-47.	0.4	2
148	Late simultaneous carcinomatous meningitis, temporal bone infiltrating macro-metastasis and disseminated multi-organ micro-metastases presenting with mono-symptomatic vertigo â€“ a clinico-pathological case reporT. Ideggyogyaszati Szemle, 2020, 73, 354-360.	0.4	2
149	Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. Ideggyogyaszati Szemle, 2013, 66, 407-14.	0.4	2
150	Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2003, 87, 272-272.	2.1	1
151	[P2â€“250]: CEREBROSPINAL FLUID LIPIDOMIC PROFILE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P708.	0.4	1
152	The assessment of possible gender-related effect of endogenous striatal alpha-tocopherol level on MPTP neurotoxicity in mice. Heliyon, 2020, 6, e04425.	1.4	1
153	Eye-tracking-aided characterization of saccades and antisaccades in SYNE1 ataxia patients: a pilot study. BMC Neuroscience, 2021, 22, 7.	0.8	1
154	Hereditary and non-hereditary etiologies associated with extensive brain calcification: case series. Metabolic Brain Disease, 2021, 36, 2131-2139.	1.4	1
155	Relationships of Ischemic Stroke Occurrence and Outcome with Gene Variants Encoding Enzymes of Tryptophan Metabolism. Biomedicines, 2021, 9, 1441.	1.4	1
156	A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report. Folia Neuropathologica, 2020, 58, 377-385.	0.5	1
157	Connection between microstructural alterations detected by diffusion MRI and cognitive dysfunction in MS: A model-free analysis approach. Multiple Sclerosis and Related Disorders, 2022, 57, 103442.	0.9	1
158	The role of cognitive training in the neurorehabilitation of a patient who survived a lightning strike. A case study. NeuroRehabilitation, 2014, 35, 137-146.	0.5	0
159	The clinical manifestations of two novel SPAST mutations. Clinical Neurology and Neurosurgery, 2015, 136, 82-85.	0.6	0
160	L13â€…Stimulation of the PGC-1A expression in mouse brain. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A94.2-A94.	0.9	0
161	Connection between small vessel disease related stroke and the MTHFR C677T polymorphism in a Hungarian population. Heliyon, 2020, 6, e05305.	1.4	0
162	Genetic epidemiological characteristics of a Hungarian subpopulation of patients with Huntingtonâ€™s disease. BMC Neurology, 2021, 21, 79.	0.8	0

#	Article	IF	Citations
163	Kynurenic acid and kynurenine aminotransferase are potential biomarkers of early neurological improvement after thrombolytic therapy: A pilot study. Advances in Clinical and Experimental Medicine, 2021, 30, 0-0.	0.6	0
164	Neuroprotection by Kynurenine Metabolites. , 2014, , 1403-1416.		0
165	Unilateral thalamic infarction causing downward gaze palsy in a patient with uncorrected tetralogy of Fallot: a case report = A lefelÃ© tekintÃ©s bÃ©nulÃ¡sÃ¡t okozÃ³ egyoldali thalamusinfarktus Fallot-tetralÃ³gia nem korrigÃ¡lt formÃ¡jÃ¡val Ã©lÅ‘ felnÅ‘ttnÃ©l: esetismertetÃ©s. Ideggyogyaszati Szemle, 2016, 69, 415-419.	0.4	0
166	Rare complication of West Nile viral encephalitis. Ideggyogyaszati Szemle, 2021, 74, 430-432.	0.4	0
167	Atypical presentation of late-onset Sandhoff disease : A case report. Ideggyogyaszati Szemle, 2021, 74, 425-429.	0.4	0
168	Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. Ideggyogyaszati Szemle, 2019, 72, 39-47.	0.4	0
169	Rare co-occurrence of multiple sclerosis and Wilsonâ€™s disease â€“ case report. BMC Neurology, 2022, 22, 178.	0.8	0